Posted by Michael Wonder on 20 May 2020
Karyopharm submits supplemental new drug application to FDA for Xpovio (selinexor) as a treatment for patients with multiple myeloma after at least one prior line of therapy
20 May 2020 - Karyopharm Therapeutics today announced it has submitted a supplemental new drug application to the U.S. FDA seeking approval for Xpovio (selinexor), its first-in-class, oral selective inhibitor of nuclear export compound, as a new treatment for patients with previously treated multiple myeloma.
Karyopharm also plans to submit a marketing authorisation application to the EMA requesting approval for Xpovio in this same indication later this year.
